Qingfeng Pharmaceutical's Class 1 innovative drug GP681 tablets made significant progress

1931
Issuing time:2020-09-17 11:10

On August 25, 2020, our clinical research team held a GP681 clinical study kick-off meeting in Shanghai Xuhui District Central Hospital, marking that our innovative drug GP681 has officially entered the phase I clinical study.


XW202009171.png


Article classification: Company News
Share to：
Qingfeng Pharmaceutical Group Co.Ltd
Location：8 Zhandong Av., Zhanggong, Ganzhou, Jiangxi Province, China
Phone：+86-0797-5560800,5560600 Fax: +86-0797-5560620